(Nasdaq: SLRN) and Alumis Inc ... with background information regarding ACELYRIN’s strategic review process, which will be available this week. Morgan Stanley & Co. LLC is serving as financial ...

(Nasdaq: SLRN) and Alumis Inc. (Nasdaq: ALMS) today reaffirmed their commitment to merge ... with the Securities and Exchange Commission with background information regarding ACELYRIN’s strategic ...

Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, ...

Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage ...

Acelyrin (NASDAQ:SLRN) traded sharply lower on Tuesday after the company and its California-based rival Alumis (NASDAQ:ALMS) reaffirmed their commitment to merge in line with their previously ...

ACELYRIN, INC. has announced that its Board of Directors has determined that an unsolicited proposal from Concentra Biosciences is unlikely to lead to a better offer than its planned all-stock ...

ACELYRIN (SLRN) (ISIN: US00445A1007)股票专题，提供今日ACELYRIN(SLRN) (ISIN: US00445A1007)股票最新股价查询，实时市场行情，走势图表，及ACELYRIN Inc(SLRN) (ISIN: US00445A1007)股票的专业技术分析，投资者论坛，历史交易数据，最新消息和未来价格预测。

(NASDAQ: SLRN) Click to Take Action ACELYRIN ... Read our editorial policy to learn more about our process.

Shares of Acelyrin, Inc. (NASDAQ: SLRN) increased 12.44% to $2.44 on Thursday after an equity-related development was confirmed. An unsolicited takeover offer from Concentra Biosciences, LLC, a ...

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...

LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines ...